Catalog No.
PMD82401
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse EPHA2 (Ala23-Ser278).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Ephrin type-A receptor 2, 2.7.10.1, Epithelial cell kinase, Tyrosine-protein kinase receptor ECK, EPHA2, ECK
Purification
Purified by antigen affinity column.
Accession
Q03145
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
R9AP is a common receptor for EBV infection in epithelial cells and B cells., PMID:40533557
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621
Eph Receptor Tyrosine Kinases Are Functional Entry Receptors for Murine Gammaherpesvirus 68., PMID:40501621
Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody., PMID:40434019
Synthetic antibodies targeting EphA2 induce diverse signaling-competent clusters with differential activation., PMID:40411427
Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications., PMID:40236294
Developing CAR-T/NK cells that target EphA2 for non-small cell lung cancer treatment., PMID:40181964
Theranostics using 89Zr/177Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2)., PMID:39934299
Targeted internalization and activation of glycosidic switch liposomes by a biological macromolecule mPEG×EphA2 increases therapeutic efficacy against lung cancer., PMID:39842595
EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation., PMID:39511410
Preclinical Characterization of XB002, an Anti-Tissue Factor Antibody-Drug Conjugate for the Treatment of Solid Tumors., PMID:39494690
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present)., PMID:39259047
Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide., PMID:39239524
In vitro analysis of single chain variable fragment-based immunotoxins against Erythropoietin-producing hepatocellular A2 receptor overexpressed in breast cancer cells., PMID:39116931
Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer., PMID:38779496
A general approach for selection of epitope-directed binders to proteins., PMID:38683990
Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer., PMID:38670584
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment., PMID:38619734
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer., PMID:38393661
Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment., PMID:38393520
Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells., PMID:38380254
Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment., PMID:38034633
An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment., PMID:37951154
Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer., PMID:37736700
Targeted Doxorubicin-Loaded Dendronized Gold Nanoparticles., PMID:37631317
Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer., PMID:37556118
Optimization of the Imaged cIEF Method for Monitoring the Charge Heterogeneity of Antibody-Maytansine Conjugate., PMID:37305029
A Designer Strategy to Develop Novel Bispecific Cancer Therapeutic Antibodies., PMID:37265411
EphA2 is a functional entry receptor for HCMV infection of glioblastoma cells., PMID:37146061
Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic., PMID:37143361
The role of EphA2 in ADAM17- and ionizing radiation-enhanced lung cancer cell migration., PMID:36998455
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy., PMID:36976175
Novel [ 111 In]In-BnDTPA-EphA2-230-1 Antibody for Single-Photon Emission Computed Tomography Imaging Tracer Targeting of EphA2., PMID:36844571
May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?, PMID:36613532
Complexity of progranulin mechanisms of action in mesothelioma., PMID:36471440
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance., PMID:36401637
Adhesion of LHRH/EphA2 to human Triple Negative Breast Cancer tissues., PMID:36195050
Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics., PMID:35708974
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers., PMID:35404015
NADPH oxidase 4 signaling in a ventilator-induced lung injury mouse model., PMID:35346198
Antibodies Targeting KSHV gH/gL Reveal Distinct Neutralization Mechanisms., PMID:35336948
Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption., PMID:35217483
Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy., PMID:34709992
Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing., PMID:34691070
Radiomics-based MRI for predicting Erythropoietin-producing hepatocellular receptor A2 expression and tumor grade in brain diffuse gliomas., PMID:34368897
Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2., PMID:34330813
EphA2 Is a Lung Epithelial Cell Receptor for Pneumocystis β-Glucans., PMID:34289046
A T cell redirection platform for co-targeting dual antigens on solid tumors., PMID:34190031
Conformation-specific monoclonal antibodies recognizing the native structure of G protein-coupled receptor (GPCR)., PMID:34182241
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas., PMID:33963009
For research use only. Not for human or drug use.
